Das Drugs Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 07-12-2024
- Paid Up Capital ₹ 3.89 Cr
as on 07-12-2024
- Company Age 27 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 15.02 Cr
as on 07-12-2024
- Revenue -0.96%
(FY 2023)
- Profit -14.55%
(FY 2023)
- Ebitda 0.92%
(FY 2023)
- Net Worth 13.27%
(FY 2023)
- Total Assets -1.44%
(FY 2023)
About Das Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 3.89 Cr.
The company currently has active open charges totaling ₹15.02 Cr.
Manoj Rastogi, Tribhuwan Das, Aruna Das, and Six other members serve as directors at the Company.
- CIN/LLPIN
U51109UP1997PTC022083
- Company No.
022083
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jun 1997
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Das Drugs?
Board Members(9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Rastogi  | Director | 05-Jun-1997 | Current |
| Anurag Das | Director | 01-Apr-1998 | Current |
| Tribhuwan Das | Director | 23-Jun-1997 | Current |
| Aruna Das | Director | 20-Jan-2015 | Current |
| Manjulata Rastogi | Director | 01-Apr-1998 | Current |
| Anupama Rastogi | Director | 17-Jun-2009 | Current |
Financial Performance of Das Drugs.
Das Drugs Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.96% decrease. The company also saw a substantial fall in profitability, with a 14.55% decrease in profit. The company's net worth Soared by an impressive increase of 13.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Das Drugs?
In 2023, Das Drugs had a promoter holding of 28.69% and a public holding of 71.31%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- M.M. Remedies Private LimitedActive 26 years 7 months
Manoj Rastogi, Tribhuwan Das and 5 more are mutual person
- Kant Drugs Private LimitedActive 23 years 10 months
Manoj Rastogi, Tribhuwan Das and 5 more are mutual person
- Four Seasons Pharmaceuticals Private LimitedActive 12 years 8 months
Tribhuwan Das is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 May 2017 | ₹7.50 M | Open |
Hdfc Bank Limited Creation Date: 29 Feb 2016 | ₹12.27 Cr | Open |
Hdfc Bank Limited Creation Date: 25 Feb 2016 | ₹2.00 Cr | Open |
How Many Employees Work at Das Drugs?
Das Drugs has a workforce of 38 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Das Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Das Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
